Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Hu

Showing results (1421-1430 of 1,603) with videos related to

Pageof 161
Sort By:
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
Journal of Medicinal Chemistry|November 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase InhibitorsDennis X Hu, Snahel Patel, Huifen Chen, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|April 30, 2022
[Course of disease and related epidemiological parameters of COVID-19: a prospective study based on contact tracing cohort]Y Zhou, W J Liang, Z H Chen, et al.
Molecular Cancer Therapeutics|August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
Circulation Research|November 3, 2017
Mitochondrial Reactive Oxygen Species in Lipotoxic Hearts Induce Post-Translational Modifications of AKAP121, DRP1, and OPA1 That Promote Mitochondrial FissionKensuke Tsushima, Heiko Bugger, Adam R Wende, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|February 25, 2024
[Epidemiological characteristics of human respiratory syncytial virus among acute respiratory infection cases in 16 provinces of China from 2009 to 2023]A L Cui, B C Xia, Z Zhu, et al.
The Journal of Hospital Infection|March 30, 2024
Epidemiology of healthcare-associated Pseudomonas aeruginosa in intensive care units: are sink drains to blame?C Volling, L Mataseje, L Graña-Miraglia, et al.
Physical Review. E|October 18, 2023
Laser-direct-drive fusion target design with a high-Z gradient-density pusher shellS X Hu, L Ceurvorst, J L Peebles, et al.
Journal of Medicinal Chemistry|July 14, 2026
Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor ImmunityOmar Robles, Dirk G Brockstedt, Joel Aponte-Guzman, et al.
Pageof 161

Showing results (1421-1430 of 1,603) with videos related to

Sort By:
Pageof 161
ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.
Journal of Medicinal Chemistry|November 15, 2021
Structure-Based Design of Potent, Selective, and Orally Bioavailable VPS34 Kinase InhibitorsDennis X Hu, Snahel Patel, Huifen Chen, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|April 30, 2022
[Course of disease and related epidemiological parameters of COVID-19: a prospective study based on contact tracing cohort]Y Zhou, W J Liang, Z H Chen, et al.
Molecular Cancer Therapeutics|August 14, 2020
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity <i>In Vitro</i> and <i>In Vivo</i>Yamini M Ohol, Michael T Sun, Gene Cutler, et al.
Circulation Research|November 3, 2017
Mitochondrial Reactive Oxygen Species in Lipotoxic Hearts Induce Post-Translational Modifications of AKAP121, DRP1, and OPA1 That Promote Mitochondrial FissionKensuke Tsushima, Heiko Bugger, Adam R Wende, et al.
ESMO Open|June 10, 2025
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06R Shami, R Salgado, A Bardia, et al.
Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]|February 25, 2024
[Epidemiological characteristics of human respiratory syncytial virus among acute respiratory infection cases in 16 provinces of China from 2009 to 2023]A L Cui, B C Xia, Z Zhu, et al.
The Journal of Hospital Infection|March 30, 2024
Epidemiology of healthcare-associated Pseudomonas aeruginosa in intensive care units: are sink drains to blame?C Volling, L Mataseje, L Graña-Miraglia, et al.
Physical Review. E|October 18, 2023
Laser-direct-drive fusion target design with a high-Z gradient-density pusher shellS X Hu, L Ceurvorst, J L Peebles, et al.
Journal of Medicinal Chemistry|July 14, 2026
Discovery of Tivumecirnon (FLX475), a Potent and Selective CCR4 Antagonist That Inhibits the Migration of Immunosuppressive Regulatory T Cells into the Tumor Microenvironment to Restore Antitumor ImmunityOmar Robles, Dirk G Brockstedt, Joel Aponte-Guzman, et al.
Pageof 161